Antengene
Help people with cancer
live longer and better.
About us

About Us

Historical Development

2014

John Gong, M.D., Ph....
2014
In 2014, John Gong, M.D., Ph.D., joined 3D Medicines and set out to develop new drug R&D platform for 3D Medicines.

John Gong, M.D., Ph.D., joined 3D Medicines and set out to develop new drug R&D platform for 3D Medicines.

2014

2015

We signed a collabor...
2015
In 2015, we signed a collaboration agreement with Beijing University of Chinese Medicine to develop and market the national Class I innovative drug with Lei Haimin's team at the School of Chinese Medi

We signed a collaboration agreement with Beijing University of Chinese Medicine to develop and market the national Class I innovative drug with Lei Haimin's team at the School of Chinese Medicine.

2015

2016

We signed a collabor...
2016
In 2016, we signed a collaboration intention with Alphamab for the global collaborative development of KN035.

We signed a collaboration intention with Alphamab for the global collaborative development of KN035.

2016

2017

- The first subject ...
2017
In 2017, we initiated the KN035 clinical trial for first patient dosing in the U.S. The first patient in China was dosed in March and Phase I clinical trial in Japan was started in August.

- The first subject was recruited in the U.S., and we initiated the KN035 clinical trial. The first subject in China was recruited in March and Phase I clinical trial in Japan was started in August.

 

- We initiated research and development of 3D011 with PCT patent application filed globally. 

2017

2018

- 3D Medicines spilt...
2018
3D Medicines spilt into 3D Medicines Inc. and 3D Diagnostics in 2018 We were granted the exclusive global development license for HaiHe Biopharma’s 3D185 in the fields of Cancer and Pulmonary Fibrosi

- 3D Medicines spilt into 3D Medicines Inc. and 3D Diagnostics.

 

- We were granted the exclusive global development license for HaiHe Biopharma’s 3D185 in the fields of Cancer and Pulmonary Fibrosis.

2018

2019

We initiated registe...
2019
We initiated registered clinical trials of KN035 in North America.

We initiated registered clinical trials of KN035 in North America.

2019

January 2020

KN035 was awarded Or
January 2020
In January, 2020, KN035 was awarded Orphan Drug Designation by FDA.

KN035 was awarded Orphan Drug Designation by FDA.

2020

March 2020

A partnership with A...
March 2020
In March, 2020, a partnership with Alphamab and Simcere Pharmaceuticals was formed for the development and commercialization of KN035 in China.

A partnership with Alphamab and Simcere Pharmaceuticals was formed for the development and commercialization of KN035 in China.

2020

October 2020

- We received $140 m...
October 2020
In October, 2020, we received $140 million investment from Simcere Pharmaceuticals, Efung Capital, China Capital Management and other institutions.

- We received $140 million investment from Simcere Pharmaceuticals, Efung Capital, China Capital Management and other institutions.

 

- A new laboratory building for Translational Medicine Center came into service, and R&D capabilities continued to grow.

 

- We signed a strategic collaboration agreement with XtalPi for drug discovery.

 

- We acquired exclusive rights to develop, manufacture, and commercialize two new analgesic molecules, RMX1001 and RMX1002, from HaiHe Biopharma in China.

2020

November 2020

- We were authorized...
November 2020
In November, 2020, Envafolimab (KN035), the world's first PD-L1 antibody drug given via subcutaneous Injection submitted new drug application for marketing in China.

- We were authorized by Aravive to exclusively develop and commercialize AVB-500, a new anti-cancer drug, in Greater China.

 

- Envafolimab (KN035), the world's first PD-L1 antibody drug given via subcutaneous Injection submitted new drug application for marketing in China.

2020

December 2020

- The NDA of Envafol...
December 2020
In December, 2020, the NDA of Envafolimab (KN035) was officially accepted by the NMPA.

- The NDA of Envafolimab (KN035) was officially accepted by the NMPA.

 

- We acquired exclusive rights for a new immuno-oncology drug in Phase 3 clinical trials in Greater China.

2020

January 2021

- We signed license ...
January 2021
In January, 2021, NDA of Envafolimab (KN035) was granted NMPA Priority Review.

- We signed license agreement with Y-Biologics on the co-development of next-generation T cell bispecific engager.

 

- NDA of Envafolimab (KN035) was granted NMPA Priority Review.

 

- IND of 3D011, the first self-developed innovative drug was approved by the NMPA.

2021

February 2021

The construction of ...
February 2021
In February, 2021, the construction of 3D Medicines’ R&D and Manufacturing Center started in Xuzhou, Jiangsu.

The construction of 3D Medicines’ R&D and Manufacturing Center started in Xuzhou, Jiangsu.

2021
2014
2015
2016
2017
2018
2019
January 2020
March 2020
October 2020
November 2020
December 2020
January 2021
February 2021
In 2014, John Gong, M.D., Ph.D., joined 3D Medicines and set out to develop new drug R&D platform for 3D Medicines.
In 2015, we signed a collaboration agreement with Beijing University of Chinese Medicine to develop and market the national Class I innovative drug with Lei Haimin's team at the School of Chinese Medi
In 2016, we signed a collaboration intention with Alphamab for the global collaborative development of KN035.
In 2017, we initiated the KN035 clinical trial for first patient dosing in the U.S. The first patient in China was dosed in March and Phase I clinical trial in Japan was started in August.
3D Medicines spilt into 3D Medicines Inc. and 3D Diagnostics in 2018 We were granted the exclusive global development license for HaiHe Biopharma’s 3D185 in the fields of Cancer and Pulmonary Fibrosi
We initiated registered clinical trials of KN035 in North America.
In January, 2020, KN035 was awarded Orphan Drug Designation by FDA.
In March, 2020, a partnership with Alphamab and Simcere Pharmaceuticals was formed for the development and commercialization of KN035 in China.
In October, 2020, we received $140 million investment from Simcere Pharmaceuticals, Efung Capital, China Capital Management and other institutions.
In November, 2020, Envafolimab (KN035), the world's first PD-L1 antibody drug given via subcutaneous Injection submitted new drug application for marketing in China.
In December, 2020, the NDA of Envafolimab (KN035) was officially accepted by the NMPA.
In January, 2021, NDA of Envafolimab (KN035) was granted NMPA Priority Review.
In February, 2021, the construction of 3D Medicines’ R&D and Manufacturing Center started in Xuzhou, Jiangsu.